Review article: Relief of symptoms in gastric acid-related diseases - Correlation with acid suppression in rabeprazole treatment

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 6, 2004, Pages 20-29

  Miner, P ^a  

^a Oklahoma Foundation for Digestive Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CISAPRIDE; CLARITHROMYCIN; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCHLORIC ACID; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; STOMACH SECRETION INHIBITOR;

CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFICACY; DUODENUM ULCER; EPIGASTRIC PAIN; GASTROINTESTINAL REFLUX; HEARTBURN; HELICOBACTER INFECTION; HUMAN; META ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID; STOMACH ACID SECRETION; STOMACH ULCER; SYMPTOM;

EID: 9944234997     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02162.x     Document Type: Review

References (53)

1. Huang JQ, Hunt RH. pH, healing rate and symptom relief in acid-related diseases. Yale J Biol Med 1996; 69: 159-74.
2. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
3. Howden CW. Optimizing the pharmacology of acid control in acid-related disorders. Am J Gastroenterol 1997; 92(Suppl. 4): 17S-21S.
4. Kaynard A, Flora K. Gastroesophageal reflux disease. Control of symptoms, prevention of complications. Postgrad Med 2001; 110: 42-4,47-8,51-3.
5. Wolfe M. An overview of gastroesophageal reflux disease. Based on a presentation by M. Michael Wolfe, MD. Am J Manag Care 2000; 6(Suppl.): S461-6.
6. Flynn CA. The evaluation and treatment of adults with gastroesophageal reflux disease. J Fam Pract 2001; 50: 61-3.
7. DiBaise JK, Lof J, Quigley EM. Can symptoms predict esophageal motor function or acid exposure in gastroesophageal reflux disease? A comparison of esophageal manometric and twenty-four-hour pH parameters in typical and extraesophageal gastroesophageal reflux disease. J Clin Gastroenterol 2001; 32: 128-32.
8. Dent J. Roles of gastric acid and pH in the pathogenesis of gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl 1994; 201: 55-61.
9. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159: 649-57.
10. Howden CW, Burget DW, Hunt RH. Appropriate acid suppression for optimal healing of duodenal ulcer and gastrooesophageal reflux disease. Scand J Gastroenterol Suppl 1994; 201: 79-82.
11. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 59-67.
12. Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276: 983-8.
13. Johnsson F, Hatlebakk JG, Klintenberg AC, Roman J. Symptom-relieving effect of esomeprazole 40 mg daily in patients with heartburn. Scand J Gastroenterol 2003; 38: 347-53.
14. Vakil N. Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 nig once daily, in healing and symptom resolution of erosive oesophagitis. Aliment Pharmacol Ther 2003; 17(Suppl. 1): 21-3.
15. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65.
16. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249-58.
17. Cloud ML, Enas N, Humphries TJ, Bassion S. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group, Dig Dis Sci 1998; 43: 993-1000.
18. Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 2002; 16: 445-54.
19. Dekkers CP, Beker JA, Thjodleifsson B, et al Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 49-57.
20. Delchier JC, Cohen G, Humphries TJ. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease. Scand J Gastroenterol 2000; 35: 1245-50.
21. Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastrooesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 479-85.
22. Breiter J, Birbara C, Moskovitz M, Barth J. Maintenance therapy with rabeprazole prevents relapse of GERD symptoms. Am J Gastroenterol 2002; 97(Suppl.): S38(Abstract 114).
23. Kristensen ES, Alstrup N, Hendel L, et al. Rabeprazole 10 mg effectively controls symptoms of gastresophageal reflux disease (GERD) over 1 year. Gastroenterology 2003; 124(Suppl. 1): A-233(Abstract).
24. Sachs G, Shin JM, Munson K, et al. Review article: the control of gastric acid and Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 1383-401.
25. Suzuki J, Mine T, Kobayasi I, Fujita T. Relationship between the eradication of Helicobacter pylori and the healing pattern of peptic ulcer. J Clin Gastroenterol 1998; 27(Suppl. 1): S159-62.
26. Hirschowitz BI. Usual and unusual causes of duodenal ulcer. Dig Liver Dis 2003; 35: 519-22.
27. Quan C, Talley NJ. Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. Am J Gastroenterol 2002; 97: 2950-61.
28. Kang JY, Yap I, Guan R, Tay HH. Acid perfusion of duodenal ulcer craters and ulcer pain: a controlled double blind study. Gut 1986; 27: 942-5.
29. Misiewicz JJ. Peptic ulceration and its correlation with symptoms. Clin Gastroenterol 1978; 7: 571-82.
30. Rune SJ, Zachariassen A. Acute relief of epigastric pain by antacid in duodenal ulcer patients. Scand J Gastroenterol Suppl 1980; 58: 41-5.
31. Quatrini M, Basilisco G, Bianchi PA. Treatment of 'cimetidine-resistant' chronic duodenal ulcers with ranitidine or cimetidine: a randomised multicentre study. Gut 1984; 25: 1113-7.
32. Texter EC Jr. Ulcer pain mechanisms. The clinical features of active peptic ulcer disease and implications for therapy. Scand J Gastroenterol Suppl 1987; 134: 1-20.
33. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash) 2000; 40: 52-62.
34. Ge ZZ, Zhang DZ, Xiao SD, Chen Y, Hu YB. Does eradication of Helicobacter pylori alone heal duodenal ulcers? Aliment Pharmacol Ther 2000; 14: 53-8.
35. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 1079-89.
36. Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 1999; 13 (Suppl. 3): 3-10.
37. Breiter JR, Riff D, Humphries TJ. Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study. Am J Gastroenterol 2000; 95: 936-42.
38. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther 1999; 13: 179-86.
39. Vakil N, Lanza F, Schwartz H, Earth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004; 20: 99-107.
40. Hawkey CJ, Atherton JC, Treichel HC, Thjodleifsson B, Ravic M. Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. Aliment Pharmacol Ther 2003; 17: 1065-74.
41. Mertz HR, Walsh JH. Peptic ulcer pathophysiology. Med Clin North Am 1991; 75: 799-814.
42. Kang JY, Yap I. Acid and gastric ulcer pain. J Clin Gastroenterol 1991; 13: 514-6.
43. Frost F, Rahbek I, Rune SJ, et al. Cimetidine in patients with gastric ulcer: a multicentre controlled trial. Br Med J 1977; 2: 795-7.
44. Eriksson S, Langstrom G, Rikner L, Carlsson R, Naesdal J. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenterol Hepatol 1995; 7: 467-75.
45. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer - a European multicentre study. The European Rabeprazole Study Group. Aliment Pharmacol Ther 1998; 12: 789-95.
46. Pass R, Fennerty MB, Vakil N. Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol 2001; 96: 303-14.
47. Pass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98(Suppl. 3): S2-7.
48. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 965-73.
49. Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000; 160: 1803-9.
50. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997; 11: 765-73.
51. Johanson J, Miner P Jr, Jokubaitis L, Ma Y, Sloan S. Rabeprazole significantly improves heartburn vs. placebo in endoscopically negative GERD patients with moderate to severe symptoms. Am J Gastroenterol 2001; 96(Suppl.): S18(Abstract).
52. Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002; 97: 1332-9.
53. Damiano A, Siddique R, Xu X, Johanson J, Sloan S. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. Dig Dis Sci 2003; 48: 657-62.